TIE2 (Y897H/R915C)

TEK · Variant type: point · HGVS: p.R915C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Repotrectinib	64.5%	35.5%	84.21
2	Ripretinib	63.7%	36.3%	92.95
3	Selpercatinib	35.7%	64.3%	96.72
4	Infigratinib	23.7%	76.3%	98.24
5	Tivozanib	22.2%	77.8%	92.42
6	Neratinib	20.8%	79.2%	93.18
7	Pemigatinib	19.8%	80.2%	98.23
8	Vandetanib	19.4%	80.6%	95.74
9	Pacritinib	13.4%	86.6%	88.64
10	Erdafitinib	13.3%	86.7%	95.71
11	Defactinib	11.3%	88.7%	92.68
12	Selumetinib	8.0%	92.0%	100.00
13	Pirtobrutinib	7.6%	92.4%	99.49
14	Mitapivat	7.3%	92.7%	100.00
15	Umbralisib	7.3%	92.7%	98.74
16	Cobimetinib	6.7%	93.3%	100.00
17	Gedatolisib	6.4%	93.6%	99.75
18	Mobocertinib	4.9%	95.1%	97.22
19	Abrocitinib	4.4%	95.6%	99.50
20	Apatinib	4.4%	95.6%	97.73
21	Tucatinib	4.4%	95.6%	99.75
22	Asciminib	2.9%	97.1%	100.00
23	Paxalisib	2.6%	97.4%	99.75
24	Sorafenib	1.4%	98.6%	96.72
25	Lazertinib	0.8%	99.2%	97.47

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Repotrectinib	64.5%	—	—
Ripretinib	63.7%	—	—
Selpercatinib	35.7%	—	—
Infigratinib	23.7%	—	—
Tivozanib	22.2%	—	—
Neratinib	20.8%	—	—
Pemigatinib	19.8%	—	—
Vandetanib	19.4%	—	—
Pacritinib	13.4%	—	—
Erdafitinib	13.3%	—	—
Defactinib	11.3%	—	—
Selumetinib	8.0%	—	—
Pirtobrutinib	7.6%	—	—
Mitapivat	7.3%	—	—
Umbralisib	7.3%	—	—
Cobimetinib	6.7%	—	—
Gedatolisib	6.4%	—	—
Mobocertinib	4.9%	—	—
Abrocitinib	4.4%	—	—
Apatinib	4.4%	—	—
Tucatinib	4.4%	—	—
Asciminib	2.9%	—	—
Paxalisib	2.6%	—	—
Sorafenib	1.4%	—	—
Lazertinib	0.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.5ms